Deepak P. Chandrasekharan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deepak P. Chandrasekharan has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Robert Edward Hynds
Epithelial Cell Biology in ENT Research (EpiCENTR) Group, Developmental Biology and Cancer Department, Great Ormond Street UCL Institute of Child Health, University College London, London, UK
16 shared publications - Sam M. Janes
Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
16 shared publications - Adam Pennycuick
UCL Respiratory, University College London, London, UK
15 shared publications - Ayse U. Akarca
Department of Cellular Pathology, University College London Hospitals, London, UK
15 shared publications - Claire Marceaux
The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
14 shared publications - Fraser R. Millar
Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XR, UK
14 shared publications
Latest Publications
- Open Access
- 31 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-21
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Patient-derived xenograft (PDX) models are widely used in cancer research. To investigate the genomic fidelity of non-small cell lung cancer PDX models, we established 48 PDX models from 22 patients enrolled in the TRACERx study. Multi-region tumor sampling increased successful PDX engraftment and most models were histologically similar to their parent tumor. Whole-exome sequencing enabled comparison of tumors and PDX models and we provide an adapted mouse reference genome for improved removal of NOD scid gamma (NSG) mouse-derived reads from sequencing data. PDX model establishment caused a genomic bottleneck, with models often representing a single tumor subclone. While distinct tumor subclones were represented in independent models from the same tumor, individual PDX models did not fully recapitulate intratumor heterogeneity. On-going genomic evolution in mice contributed modestly to the genomic distance between tumors and PDX models. Our study highlights the importance of considering primary tumor heterogeneity when using PDX models and emphasizes the benefit of comprehensive tumor sampling.
- 31 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-21
Open AccessRepresentation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Patient-derived xenograft (PDX) models are widely used in cancer research. To investigate the genomic fidelity of non-small cell lung cancer PDX models, we established 48 PDX models from 22 patients enrolled in the TRACERx study. Multi-region tumor sampling increased successful PDX engraftment and most models were histologically similar to their parent tumor. Whole-exome sequencing enabled comparison of tumors and PDX models and we provide an adapted mouse reference genome for improved removal of NOD scid gamma (NSG) mouse-derived reads from sequencing data. PDX model establishment caused a genomic bottleneck, with models often representing a single tumor subclone. While distinct tumor subclones were represented in independent models from the same tumor, individual PDX models did not fully recapitulate intratumor heterogeneity. On-going genomic evolution in mice contributed modestly to the genomic distance between tumors and PDX models. Our study highlights the importance of considering primary tumor heterogeneity when using PDX models and emphasizes the benefit of comprehensive tumor sampling.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Pathway analysis comparing the illumina and Affymetrix datasets as described in Supplementary Methods.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Pathway analysis comparing the illumina and Affymetrix datasets as described in Supplementary Methods.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Immune cell deconvolution from molecular data. Relative proportions of immune cell subtypes are predicted from gene expression data using the Danaher method, and from methylation data using methylCIBERSORT. Differences between progressive and regressive groups are reported here.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Immune cell deconvolution from molecular data. Relative proportions of immune cell subtypes are predicted from gene expression data using the Danaher method, and from methylation data using methylCIBERSORT. Differences between progressive and regressive groups are reported here.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Markers used to define cell types in quantitative multiplex immunohistochemistry experiments.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Markers used to define cell types in quantitative multiplex immunohistochemistry experiments.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Details of molecular investigations performed on each sample. Clinical and outcome data is also presented. In all cases with a previous history of lung cancer, this was of squamous histology.